Michael Redd Promoted to President of Major Pharmaceuticals

April 12, 2010 - PRLog -- Livonia, MI (January 11, 2010) Major Pharmaceuticals. a leading national supplier
of branded and generic pharmaceuticals today announced that Michael Redd has
been promoted to President from Senior Vice President.

In his new role as President, Redd will lead all functions of the company, including sales,
operations, product launch, marketing and finance. In his role as Senior Vice President, Redd was instrumental in positioning Major Pharmaceuticals to become one of the premier suppliers of Rx pharmaceuticals, OTCs and vitamins.

"Michael Redd has a proven track record of providing exceptional vision and
leadership to the organization and will continue to drive growth for the company in
his new role as President," said Randolph J. Friedman, Chairman and Chief Executive
Officer of The Harvard Drug Group LLC, Parent company of Major Pharmaceuticals.
Redd joined Major Pharmaceuticals in 2001. Prior to that, he served as Field Director
of Managed Care at Carnrick Laboratories, Inc. which operates as a subsidiary of
Elan Corporation, plc.

About Major Pharmaceuticals
MAJOR Pharmaceuticals (Majorpharmaceuticals.com) is a leading national supplier of Rx
pharmaceuticals, Unit Dose and over-the-counter drugs in the Institutional (non-retail)
market. The company offers products equivalent to national brands in quality, formula, size
and structure, for a fraction of the cost. The company sells to over 6,000 customers, including wholesalers, distributors, government agencies, hospitals, and long term care companies. Founded in 1967, Major Pharmaceuticals has grown to be the second largest generics-focused pharmaceutical distributor in the United States. The company has headquarters in Livonia, Michigan.

# # #

MAJOR Pharmaceuticals is a leading supplier of Rx, Unit Dose and OTCs to the Institutional, Retail and Non-Retail markets. Providing brand products equivalents to national brands in quality, formula, size and structure, for a fraction of the cost.